Novel Methods for Enhanced Efficacy of Mesenchymal Stem Cells

Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nature Immunology, 2014 Nov; 15(11):1009-16


Invention Summary:

Clinical studies have shown that treatment with mesenchymal stem cells (MSCs) improves the condition of a number of diseases. It is generally believed that MSC-based therapy not only provides a source of cells for reconstituting tissues, but also regulates inflammation and “empowers” other cells to facilitate tissue repair. In response to inflammatory mediators, MSCs produce ample amounts of immunoregulatory factors, cell-mobilization factors and growth factors, and thereby facilitate tissue repair by tissue-resident stem cells. The crosstalk between MSCs and inflammation is considered to be critical for the therapeutic efficacy of these cells.

Rutgers investigators discovered that the ability of MSCs to “empower” other cells to facilitate tissue repair can be enhanced dramatically by certain inflammatory cytokines. In vivo experiments showed that MSCs pretreated with certain combinations of inflammatory cytokines together could effectively cure concanavalin A (ConA)-induced liver injury in mice. Proprietary methods and kits have been developed to pretreat MSCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, SLE, sepsis, hepatitis, cirrhosis, Parkinson’s disease, chronic infections and GvHD.

Market Application:

Stem cell therapy for multiple sclerosis, arthritis, SLE, inflammatory bowel disease, sepsis, hepatitis, cirrhosis, Parkinson’s disease, chronic infections and GvHD.

Advantages:

  • Better application of MSCs in clinical settings
  • Therapeutic effect can be augmented by 50 to 90%
  • Ease of implementation
  • Improve the consistency of the immune modulatory effects in patients with different inflammatory statuses
  • Pretreatment to enhance the production of regeneration factors


Intellectual Property & Development Status:

Issued and pending patents; available for licensing and/or collaboration.

Rutgers ID: S12-055
Category(s):
Life Sciences
Therapeutics
Contact:
Shan Wan
Senior Licensing Manager
(848) 932-4468
shanwan@rutgers.edu
Inventors:
Yufang Shi
Guangwen Ren
Liying Zhang
Keywords: